{"id":32590,"date":"2025-07-30T08:44:04","date_gmt":"2025-07-30T08:44:04","guid":{"rendered":"https:\/\/ibima.eu\/estudio-de-fase-iii-abierto-aleatorizado-perioperatorio-de-dostarlimab-en-monoterapia-frente-al-tratamiento-estandar-en-pacientes-con-cancer-de-colon-resecable-con-perdida-del-mecanismo-de-reparacio\/"},"modified":"2025-07-30T08:44:04","modified_gmt":"2025-07-30T08:44:04","slug":"estudio-de-fase-iii-abierto-aleatorizado-perioperatorio-de-dostarlimab-en-monoterapia-frente-al-tratamiento-estandar-en-pacientes-con-cancer-de-colon-resecable-con-perdida-del-mecanismo-de-reparacio","status":"publish","type":"post","link":"https:\/\/ibima.eu\/es\/estudio-de-fase-iii-abierto-aleatorizado-perioperatorio-de-dostarlimab-en-monoterapia-frente-al-tratamiento-estandar-en-pacientes-con-cancer-de-colon-resecable-con-perdida-del-mecanismo-de-reparacio\/","title":{"rendered":"Estudio de fase III abierto, aleatorizado, perioperatorio de Dostarlimab en monoterapia frente al tratamiento est\u00e1ndar en pacientes con c\u00e1ncer de colon resecable con p\u00e9rdida del mecanismo de reparaci\u00f3n de apareamiento de bases (dMMR)\/inestabilidad de microsat\u00e9lites alta (MSI-H), T4N0 o estadio III, no tratado. AZUR 2"},"content":{"rendered":"<p>ESPERANZA TORRES S\u00c1NCHEZ &#8211; ENSAYO CLINICO CON MEDICAMENTOS &#8211; III &#8211; GLAXOSMITHKLINE, S.A.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>ESPERANZA TORRES S\u00c1NCHEZ &#8211; ENSAYO CLINICO CON MEDICAMENTOS &#8211; III &#8211; GLAXOSMITHKLINE, S.A.<\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_et_pb_use_builder":"","_et_pb_old_content":"","_et_gb_content_width":"","footnotes":""},"categories":[2263,2295],"tags":[],"class_list":["post-32590","post","type-post","status-publish","format-standard","hentry","category-ensayos-clinicos","category-ensayos-clinicos-b-01-ensayos-clinicos"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.3 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Estudio de fase III abierto, aleatorizado, perioperatorio de Dostarlimab en monoterapia frente al tratamiento est\u00e1ndar en pacientes con c\u00e1ncer de colon resecable con p\u00e9rdida del mecanismo de reparaci\u00f3n de apareamiento de bases (dMMR)\/inestabilidad de microsat\u00e9lites alta (MSI-H), T4N0 o estadio III, no tratado. AZUR 2 - Ibima<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/ibima.eu\/es\/estudio-de-fase-iii-abierto-aleatorizado-perioperatorio-de-dostarlimab-en-monoterapia-frente-al-tratamiento-estandar-en-pacientes-con-cancer-de-colon-resecable-con-perdida-del-mecanismo-de-reparacio\/\" \/>\n<meta property=\"og:locale\" content=\"es_ES\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Estudio de fase III abierto, aleatorizado, perioperatorio de Dostarlimab en monoterapia frente al tratamiento est\u00e1ndar en pacientes con c\u00e1ncer de colon resecable con p\u00e9rdida del mecanismo de reparaci\u00f3n de apareamiento de bases (dMMR)\/inestabilidad de microsat\u00e9lites alta (MSI-H), T4N0 o estadio III, no tratado. AZUR 2 - Ibima\" \/>\n<meta property=\"og:description\" content=\"ESPERANZA TORRES S\u00c1NCHEZ &#8211; ENSAYO CLINICO CON MEDICAMENTOS &#8211; III &#8211; GLAXOSMITHKLINE, S.A.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/ibima.eu\/es\/estudio-de-fase-iii-abierto-aleatorizado-perioperatorio-de-dostarlimab-en-monoterapia-frente-al-tratamiento-estandar-en-pacientes-con-cancer-de-colon-resecable-con-perdida-del-mecanismo-de-reparacio\/\" \/>\n<meta property=\"og:site_name\" content=\"Ibima\" \/>\n<meta property=\"article:published_time\" content=\"2025-07-30T08:44:04+00:00\" \/>\n<meta name=\"author\" content=\"prodriguez\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Escrito por\" \/>\n\t<meta name=\"twitter:data1\" content=\"prodriguez\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/ibima.eu\\\/estudio-de-fase-iii-abierto-aleatorizado-perioperatorio-de-dostarlimab-en-monoterapia-frente-al-tratamiento-estandar-en-pacientes-con-cancer-de-colon-resecable-con-perdida-del-mecanismo-de-reparacio\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/ibima.eu\\\/estudio-de-fase-iii-abierto-aleatorizado-perioperatorio-de-dostarlimab-en-monoterapia-frente-al-tratamiento-estandar-en-pacientes-con-cancer-de-colon-resecable-con-perdida-del-mecanismo-de-reparacio\\\/\"},\"author\":{\"name\":\"prodriguez\",\"@id\":\"https:\\\/\\\/ibima.eu\\\/es\\\/#\\\/schema\\\/person\\\/40b410344dd5ad2315bb651e3fbfa635\"},\"headline\":\"Estudio de fase III abierto, aleatorizado, perioperatorio de Dostarlimab en monoterapia frente al tratamiento est\u00e1ndar en pacientes con c\u00e1ncer de colon resecable con p\u00e9rdida del mecanismo de reparaci\u00f3n de apareamiento de bases (dMMR)\\\/inestabilidad de microsat\u00e9lites alta (MSI-H), T4N0 o estadio III, no tratado. AZUR 2\",\"datePublished\":\"2025-07-30T08:44:04+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/ibima.eu\\\/estudio-de-fase-iii-abierto-aleatorizado-perioperatorio-de-dostarlimab-en-monoterapia-frente-al-tratamiento-estandar-en-pacientes-con-cancer-de-colon-resecable-con-perdida-del-mecanismo-de-reparacio\\\/\"},\"wordCount\":66,\"commentCount\":0,\"articleSection\":[\"Ensayos Cl\u00ednicos\",\"Ensayos Cl\u00ednicos - B-01\"],\"inLanguage\":\"es\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/ibima.eu\\\/estudio-de-fase-iii-abierto-aleatorizado-perioperatorio-de-dostarlimab-en-monoterapia-frente-al-tratamiento-estandar-en-pacientes-con-cancer-de-colon-resecable-con-perdida-del-mecanismo-de-reparacio\\\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/ibima.eu\\\/estudio-de-fase-iii-abierto-aleatorizado-perioperatorio-de-dostarlimab-en-monoterapia-frente-al-tratamiento-estandar-en-pacientes-con-cancer-de-colon-resecable-con-perdida-del-mecanismo-de-reparacio\\\/\",\"url\":\"https:\\\/\\\/ibima.eu\\\/estudio-de-fase-iii-abierto-aleatorizado-perioperatorio-de-dostarlimab-en-monoterapia-frente-al-tratamiento-estandar-en-pacientes-con-cancer-de-colon-resecable-con-perdida-del-mecanismo-de-reparacio\\\/\",\"name\":\"Estudio de fase III abierto, aleatorizado, perioperatorio de Dostarlimab en monoterapia frente al tratamiento est\u00e1ndar en pacientes con c\u00e1ncer de colon resecable con p\u00e9rdida del mecanismo de reparaci\u00f3n de apareamiento de bases (dMMR)\\\/inestabilidad de microsat\u00e9lites alta (MSI-H), T4N0 o estadio III, no tratado. AZUR 2 - Ibima\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/ibima.eu\\\/es\\\/#website\"},\"datePublished\":\"2025-07-30T08:44:04+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/ibima.eu\\\/es\\\/#\\\/schema\\\/person\\\/40b410344dd5ad2315bb651e3fbfa635\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/ibima.eu\\\/estudio-de-fase-iii-abierto-aleatorizado-perioperatorio-de-dostarlimab-en-monoterapia-frente-al-tratamiento-estandar-en-pacientes-con-cancer-de-colon-resecable-con-perdida-del-mecanismo-de-reparacio\\\/#breadcrumb\"},\"inLanguage\":\"es\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/ibima.eu\\\/estudio-de-fase-iii-abierto-aleatorizado-perioperatorio-de-dostarlimab-en-monoterapia-frente-al-tratamiento-estandar-en-pacientes-con-cancer-de-colon-resecable-con-perdida-del-mecanismo-de-reparacio\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/ibima.eu\\\/estudio-de-fase-iii-abierto-aleatorizado-perioperatorio-de-dostarlimab-en-monoterapia-frente-al-tratamiento-estandar-en-pacientes-con-cancer-de-colon-resecable-con-perdida-del-mecanismo-de-reparacio\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Portada\",\"item\":\"https:\\\/\\\/ibima.eu\\\/es\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Estudio de fase III abierto, aleatorizado, perioperatorio de Dostarlimab en monoterapia frente al tratamiento est\u00e1ndar en pacientes con c\u00e1ncer de colon resecable con p\u00e9rdida del mecanismo de reparaci\u00f3n de apareamiento de bases (dMMR)\\\/inestabilidad de microsat\u00e9lites alta (MSI-H), T4N0 o estadio III, no tratado. AZUR 2\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/ibima.eu\\\/es\\\/#website\",\"url\":\"https:\\\/\\\/ibima.eu\\\/es\\\/\",\"name\":\"Ibima\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/ibima.eu\\\/es\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"es\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/ibima.eu\\\/es\\\/#\\\/schema\\\/person\\\/40b410344dd5ad2315bb651e3fbfa635\",\"name\":\"prodriguez\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/3e682b55f425f54644efd95284b890bfd6e129cc61dd791a9d4345ce1ed26791?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/3e682b55f425f54644efd95284b890bfd6e129cc61dd791a9d4345ce1ed26791?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/3e682b55f425f54644efd95284b890bfd6e129cc61dd791a9d4345ce1ed26791?s=96&d=mm&r=g\",\"caption\":\"prodriguez\"},\"sameAs\":[\"https:\\\/\\\/ibima.eu\"],\"url\":\"https:\\\/\\\/ibima.eu\\\/es\\\/author\\\/prodriguez\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Estudio de fase III abierto, aleatorizado, perioperatorio de Dostarlimab en monoterapia frente al tratamiento est\u00e1ndar en pacientes con c\u00e1ncer de colon resecable con p\u00e9rdida del mecanismo de reparaci\u00f3n de apareamiento de bases (dMMR)\/inestabilidad de microsat\u00e9lites alta (MSI-H), T4N0 o estadio III, no tratado. AZUR 2 - Ibima","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/ibima.eu\/es\/estudio-de-fase-iii-abierto-aleatorizado-perioperatorio-de-dostarlimab-en-monoterapia-frente-al-tratamiento-estandar-en-pacientes-con-cancer-de-colon-resecable-con-perdida-del-mecanismo-de-reparacio\/","og_locale":"es_ES","og_type":"article","og_title":"Estudio de fase III abierto, aleatorizado, perioperatorio de Dostarlimab en monoterapia frente al tratamiento est\u00e1ndar en pacientes con c\u00e1ncer de colon resecable con p\u00e9rdida del mecanismo de reparaci\u00f3n de apareamiento de bases (dMMR)\/inestabilidad de microsat\u00e9lites alta (MSI-H), T4N0 o estadio III, no tratado. AZUR 2 - Ibima","og_description":"ESPERANZA TORRES S\u00c1NCHEZ &#8211; ENSAYO CLINICO CON MEDICAMENTOS &#8211; III &#8211; GLAXOSMITHKLINE, S.A.","og_url":"https:\/\/ibima.eu\/es\/estudio-de-fase-iii-abierto-aleatorizado-perioperatorio-de-dostarlimab-en-monoterapia-frente-al-tratamiento-estandar-en-pacientes-con-cancer-de-colon-resecable-con-perdida-del-mecanismo-de-reparacio\/","og_site_name":"Ibima","article_published_time":"2025-07-30T08:44:04+00:00","author":"prodriguez","twitter_card":"summary_large_image","twitter_misc":{"Escrito por":"prodriguez"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/ibima.eu\/estudio-de-fase-iii-abierto-aleatorizado-perioperatorio-de-dostarlimab-en-monoterapia-frente-al-tratamiento-estandar-en-pacientes-con-cancer-de-colon-resecable-con-perdida-del-mecanismo-de-reparacio\/#article","isPartOf":{"@id":"https:\/\/ibima.eu\/estudio-de-fase-iii-abierto-aleatorizado-perioperatorio-de-dostarlimab-en-monoterapia-frente-al-tratamiento-estandar-en-pacientes-con-cancer-de-colon-resecable-con-perdida-del-mecanismo-de-reparacio\/"},"author":{"name":"prodriguez","@id":"https:\/\/ibima.eu\/es\/#\/schema\/person\/40b410344dd5ad2315bb651e3fbfa635"},"headline":"Estudio de fase III abierto, aleatorizado, perioperatorio de Dostarlimab en monoterapia frente al tratamiento est\u00e1ndar en pacientes con c\u00e1ncer de colon resecable con p\u00e9rdida del mecanismo de reparaci\u00f3n de apareamiento de bases (dMMR)\/inestabilidad de microsat\u00e9lites alta (MSI-H), T4N0 o estadio III, no tratado. AZUR 2","datePublished":"2025-07-30T08:44:04+00:00","mainEntityOfPage":{"@id":"https:\/\/ibima.eu\/estudio-de-fase-iii-abierto-aleatorizado-perioperatorio-de-dostarlimab-en-monoterapia-frente-al-tratamiento-estandar-en-pacientes-con-cancer-de-colon-resecable-con-perdida-del-mecanismo-de-reparacio\/"},"wordCount":66,"commentCount":0,"articleSection":["Ensayos Cl\u00ednicos","Ensayos Cl\u00ednicos - B-01"],"inLanguage":"es","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/ibima.eu\/estudio-de-fase-iii-abierto-aleatorizado-perioperatorio-de-dostarlimab-en-monoterapia-frente-al-tratamiento-estandar-en-pacientes-con-cancer-de-colon-resecable-con-perdida-del-mecanismo-de-reparacio\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/ibima.eu\/estudio-de-fase-iii-abierto-aleatorizado-perioperatorio-de-dostarlimab-en-monoterapia-frente-al-tratamiento-estandar-en-pacientes-con-cancer-de-colon-resecable-con-perdida-del-mecanismo-de-reparacio\/","url":"https:\/\/ibima.eu\/estudio-de-fase-iii-abierto-aleatorizado-perioperatorio-de-dostarlimab-en-monoterapia-frente-al-tratamiento-estandar-en-pacientes-con-cancer-de-colon-resecable-con-perdida-del-mecanismo-de-reparacio\/","name":"Estudio de fase III abierto, aleatorizado, perioperatorio de Dostarlimab en monoterapia frente al tratamiento est\u00e1ndar en pacientes con c\u00e1ncer de colon resecable con p\u00e9rdida del mecanismo de reparaci\u00f3n de apareamiento de bases (dMMR)\/inestabilidad de microsat\u00e9lites alta (MSI-H), T4N0 o estadio III, no tratado. AZUR 2 - Ibima","isPartOf":{"@id":"https:\/\/ibima.eu\/es\/#website"},"datePublished":"2025-07-30T08:44:04+00:00","author":{"@id":"https:\/\/ibima.eu\/es\/#\/schema\/person\/40b410344dd5ad2315bb651e3fbfa635"},"breadcrumb":{"@id":"https:\/\/ibima.eu\/estudio-de-fase-iii-abierto-aleatorizado-perioperatorio-de-dostarlimab-en-monoterapia-frente-al-tratamiento-estandar-en-pacientes-con-cancer-de-colon-resecable-con-perdida-del-mecanismo-de-reparacio\/#breadcrumb"},"inLanguage":"es","potentialAction":[{"@type":"ReadAction","target":["https:\/\/ibima.eu\/estudio-de-fase-iii-abierto-aleatorizado-perioperatorio-de-dostarlimab-en-monoterapia-frente-al-tratamiento-estandar-en-pacientes-con-cancer-de-colon-resecable-con-perdida-del-mecanismo-de-reparacio\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/ibima.eu\/estudio-de-fase-iii-abierto-aleatorizado-perioperatorio-de-dostarlimab-en-monoterapia-frente-al-tratamiento-estandar-en-pacientes-con-cancer-de-colon-resecable-con-perdida-del-mecanismo-de-reparacio\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Portada","item":"https:\/\/ibima.eu\/es\/"},{"@type":"ListItem","position":2,"name":"Estudio de fase III abierto, aleatorizado, perioperatorio de Dostarlimab en monoterapia frente al tratamiento est\u00e1ndar en pacientes con c\u00e1ncer de colon resecable con p\u00e9rdida del mecanismo de reparaci\u00f3n de apareamiento de bases (dMMR)\/inestabilidad de microsat\u00e9lites alta (MSI-H), T4N0 o estadio III, no tratado. AZUR 2"}]},{"@type":"WebSite","@id":"https:\/\/ibima.eu\/es\/#website","url":"https:\/\/ibima.eu\/es\/","name":"Ibima","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/ibima.eu\/es\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"es"},{"@type":"Person","@id":"https:\/\/ibima.eu\/es\/#\/schema\/person\/40b410344dd5ad2315bb651e3fbfa635","name":"prodriguez","image":{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/secure.gravatar.com\/avatar\/3e682b55f425f54644efd95284b890bfd6e129cc61dd791a9d4345ce1ed26791?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/3e682b55f425f54644efd95284b890bfd6e129cc61dd791a9d4345ce1ed26791?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/3e682b55f425f54644efd95284b890bfd6e129cc61dd791a9d4345ce1ed26791?s=96&d=mm&r=g","caption":"prodriguez"},"sameAs":["https:\/\/ibima.eu"],"url":"https:\/\/ibima.eu\/es\/author\/prodriguez\/"}]}},"_links":{"self":[{"href":"https:\/\/ibima.eu\/es\/wp-json\/wp\/v2\/posts\/32590","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/ibima.eu\/es\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/ibima.eu\/es\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/ibima.eu\/es\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/ibima.eu\/es\/wp-json\/wp\/v2\/comments?post=32590"}],"version-history":[{"count":3,"href":"https:\/\/ibima.eu\/es\/wp-json\/wp\/v2\/posts\/32590\/revisions"}],"predecessor-version":[{"id":55647,"href":"https:\/\/ibima.eu\/es\/wp-json\/wp\/v2\/posts\/32590\/revisions\/55647"}],"wp:attachment":[{"href":"https:\/\/ibima.eu\/es\/wp-json\/wp\/v2\/media?parent=32590"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/ibima.eu\/es\/wp-json\/wp\/v2\/categories?post=32590"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/ibima.eu\/es\/wp-json\/wp\/v2\/tags?post=32590"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}